Tags : PMDA


Merck’s Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3

Shots: •      Out of 5 approvals three are for NSCLC patients, one for Melanoma and one for Microsatellite Instability-High (MSI-H) solid tumor patients •      Keytruda got approved as monotherapy in 1L PD-L1 positive NSCLC patients based on Keynote-042, one in 1L non-squamous patients in combination with pemetrexed and PT-CT based on keynote-189 and another for […]Read More